🔓 Unlock the full profile of Armen Margaryan (Noymed Cro), including verified contact details, financial insights, and professional associations.
See Armen Margaryan Full Profile 🔥 Explore Money in MotionBelow are the ✅ Verified Contact Details to help you connect directly:
Email: arm*****@noy******.com
Mobile: 96008*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Armen Margaryan is a cofounder and the CEO of NoyMed CRO, a clinical research organization founded in 2012, which focuses on supporting clinical trials and research initiatives.
- Under Armen Margaryan's leadership, NoyMed CRO has established a reputation for efficiency and innovation in clinical research services.
- Prior to NoyMed CRO, Armen held several significant positions at Margasoft Corp, serving as CEO from February 2016 to February 2021 and as VP of Software Development from May 2011 to January 2016.
- During the tenure at Margasoft Corp, Armen contributed to the company's growth and development in software solutions, guiding multiple projects that enhanced operational efficiency.
- Armen's background includes extensive experience in software development, having started as a Software Engineer at Home Organizers, Inc. in 2004, reflecting a solid foundation in technology and innovation.
- NoyMed CRO has seen fluctuations in organizational growth, with a noted 12-month headcount growth decline of approximately 5.9% and a 24-month decline of about 17.2%, indicating challenges faced in scaling the company.
- The company offers a variety of services, including data management, clinical monitoring, and regulatory support, ultimately contributing to the advancement of healthcare solutions.
- Armen Margaryan actively engages with the broader healthcare community through networking and partnerships, leveraging connections to foster collaboration and expand NoyMed CRO's impact.
- With a focus on patient-centered research, Armen is committed to advancing methodologies that improve clinical trial design and execution, thereby enhancing the overall quality of medical research.